Literature DB >> 21518976

Preoperative factors associated with adverse outcome after tricuspid valve replacement.

Yan Topilsky1, Amber D Khanna, Jae K Oh, Rick A Nishimura, Maurice Enriquez-Sarano, Yang B Jeon, Thoralf M Sundt, Hartzell V Schaff, Soon J Park.   

Abstract

BACKGROUND: Preoperative factors associated with increased mortality and worse outcome after tricuspid valve replacement in patients with severe tricuspid regurgitation are poorly understood. METHODS AND
RESULTS: We retrospectively analyzed 189 patients (37% men; age, 67.5±11.3 years) who underwent tricuspid valve replacement for severe tricuspid regurgitation. Operative mortality rate was 10%, and was associated with intra-aortic balloon pump (odds ratio, 3.2; 95% confidence interval, 1.9 to 5.6; P<0.0001) or the presence of severe symptoms (New York Heart Association class IV relative to classes II and/or III) at the time of surgery (1.7; 95% confidence interval, 1.05 to 2.8; P=0.02). At the end of follow-up (29.3±27.1 months), 70 patients (37%) died, 6 (3%) needed tricuspid reoperation, and 41 (21.7%) were readmitted for heart failure. Seventy-eight patients (41.3%) were free from cardiovascular events (death, tricuspid reoperation, or heart failure admissions). The only echocardiographic parameter independently associated with adverse outcomes was a decrease in the right index of myocardial performance ratio. All-cause mortality was independently associated with a higher Charlson index (hazard ratio, 1.18; 95% confidence interval, 1.01 to 1.36; P=0.03), shorter right index of myocardial performance ratio (0.91; 95% confidence interval, 0.87 to 0.96; P=0.005), and preoperative New York Heart Association IV class (1.71; 95% confidence interval, 1.3 to 2.2; P<0.0001). In 68 patients with isolated tricuspid valve replacement, the associations between short right index of myocardial performance ratio, high Charlson index, New York Heart Association class IV, and increased mortality remained significant.
CONCLUSIONS: Tricuspid valve replacement for severe tricuspid regurgitation can be performed with an acceptable operative mortality if patients undergo surgery before the onset of advanced heart failure symptoms. Late mortality is associated with a high preoperative Charlson index, short right index of myocardial performance ratio, and advanced New York Heart Association class.

Entities:  

Mesh:

Year:  2011        PMID: 21518976     DOI: 10.1161/CIRCULATIONAHA.110.991018

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  38 in total

Review 1.  Tricuspid regurgitation: pathophysiology and management.

Authors:  Rashmi Thapa; Buddhadeb Dawn; Jayant Nath
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

2.  The ideal substitute for tricuspid valve replacement in patients with congenital heart disease: an unsolved dilemma.

Authors:  Andrea Garatti; Alessandro Giamberti; Alessandro Frigiola; Lorenzo Menicanti
Journal:  Transl Pediatr       Date:  2017-04

Review 3.  Current Treatment Strategies for Tricuspid Regurgitation.

Authors:  Mohammed Al-Hijji; Erin A Fender; Abdallah El Sabbagh; David R Holmes
Journal:  Curr Cardiol Rep       Date:  2017-09-14       Impact factor: 2.931

4.  Interventional treatment of tricuspid regurgitation : An important innovation in cardiology.

Authors:  Georg Goliasch; Julia Mascherbauer
Journal:  Wien Klin Wochenschr       Date:  2020-02       Impact factor: 1.704

Review 5.  How to Treat Tricuspid Valve Disease: What's New on the Horizon?

Authors:  Karina Brüstle; Christelle Calen; Shingo Kuwata; Fabian Nietlispach; Michel Zuber; Francesco Maisano; Maurizio Taramasso
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-03

Review 6.  Tricuspid regurgitation after successful mitral valve surgery.

Authors:  Vasiliki Katsi; Leonidas Raftopoulos; Constantina Aggeli; Ioannis Vlasseros; Ioannis Felekos; Dimitrios Tousoulis; Christodoulos Stefanadis; Ioannis Kallikazaros
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-03-28

Review 7.  [MitraClip® for treatment of tricuspid valve insufficiency].

Authors:  R Pfister; S Baldus
Journal:  Herz       Date:  2017-11       Impact factor: 1.443

Review 8.  Transcatheter therapies for severe tricuspid regurgitation. Quo vadis?

Authors:  Brunilda Alushi; Kourosh Vathie; Holger Thiele; Alexander Lauten
Journal:  Herz       Date:  2020-05-28       Impact factor: 1.443

9.  Indications for Surgery for Tricuspid Regurgitation.

Authors:  Yan Topilsky
Journal:  Interv Cardiol       Date:  2015-03

10.  Isolated tricuspid valve surgery at a single centre: the 47-year Auckland experience, 1965-2011.

Authors:  Timothy H Oh; Tom K Wang; Karishma Sidhu; David A Haydock
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.